


COMPLETE LISTING OF ALL CLAIMS, WITH MARKINGS AND STATUS IDENTIFIERS
(Currently amended claims showing deletions by ~~striking through~~ and additions by underlining)

In the Claims

1-16. (Canceled)

17. (Currently amended) A pharmaceutical composition ~~according to claim 16,~~
comprising an anthracycline, or a pharmaceutically acceptable salt thereof, and a
farnesyl transferase inhibitor, wherein said farnesyl transferase inhibitor is:



or a pharmaceutically acceptable salt thereof.

18. (Previously presented) A pharmaceutical composition according to claim 17,
wherein said anthracycline is doxorubicin, daunorubicin, epirubicin, idarubicin, or
amrubicin, or a pharmaceutically acceptable salt thereof.

19. (Previously presented) A pharmaceutical composition according to claim 17,
wherein said anthracycline is doxorubicin, or a pharmaceutically acceptable salt thereof.

20-21. (Canceled)

22. (Currently amended) A method of decreasing the rate of proliferation of
nasopharyngeal carcinoma cells, said method comprising contacting said
nasopharyngeal cells with a pharmaceutical composition according to any one of claims

[[18]] 17 – [[21]] 19.

23 – 25. (Canceled)

26. (Currently amended) A method of treating nasopharyngeal carcinoma in a patient, said method comprising administering to said patient a therapeutically effective amount of a pharmaceutical composition according to any one of claims [[18]] 17 – [[21]] 19, wherein said effective amount of said combination is effective to treat said nasopharyngeal carcinoma.

27 – 30. (Canceled)

31. (Currently amended) A method according to claim [[30]] 26 wherein said patient is a mammal.

32. (Currently amended) A method according to claim [[31]] 26 wherein said patient is a human being.

33 - 40. (Canceled)